Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review ; day:6 ; month:3 ; year:2021 ; pages:1-14
European journal of nuclear medicine and molecular imaging ; (6.3.2021), 1-14
- Creator
-
Manafi-Farid, Reyhaneh
Harsini, Sara
Saidi, Bahare
Ahmadzadehfar, Hojat
Herrmann, Ken
Briganti, Alberto
Walz, Jochen
Beheshti, Mohsen
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-021-05237-y
- URN
-
urn:nbn:de:101:1-2021041920152446108677
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Manafi-Farid, Reyhaneh
- Harsini, Sara
- Saidi, Bahare
- Ahmadzadehfar, Hojat
- Herrmann, Ken
- Briganti, Alberto
- Walz, Jochen
- Beheshti, Mohsen
- SpringerLink (Online service)
Other Objects (12)
![2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke](/assets/placeholder/searchResultMediaUnknown.png)
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Assoziation zwischen molekularpathologischen Alterationen beim papillären Schilddrüsenkarzinom und dem Auftreten einer radiojodrefraktären Erkrankung
Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?
Early PSA change after [177Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Affordable and personalized solutions for radiation therapy of superficial skin tumors : [kumulative Dissertation]
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Assoziation zwischen molekularpathologischen Alterationen beim papillären Schilddrüsenkarzinom und dem Auftreten einer radiojodrefraktären Erkrankung
Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?
Early PSA change after [177Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Affordable and personalized solutions for radiation therapy of superficial skin tumors : [kumulative Dissertation]
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Assoziation zwischen molekularpathologischen Alterationen beim papillären Schilddrüsenkarzinom und dem Auftreten einer radiojodrefraktären Erkrankung
Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?
Early PSA change after [177Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T